Introduction
Receptor tyrosine kinases (RTK) form a large family of growth factor receptors and are considered to play important roles in pleiotropic cell functions (1) . To date, numerous RTK have been isolated from hematopoietic progenitor cells by RT-PCR, indicating their involvement in hematopoiesis (2) (3) (4) . Among RTK family members, c-KIT and FLK2/FLT3 (fetal liver kinase 2/fms-like tyrosine kinase 3) have been well characterized in hematopoietic stem cells (HSC) as the receptors of hematopoietic growth factors: stem cell factor/kit ligand (SCF/KL) and FLK2/FLT3 ligand (FL) respectively (5, 6) .
TIE (tyrosine kinase with Ig-like loops and epidermal growth factor homology domains) and TEK (tunica interna endothelial the normal range, suggesting that these receptors are not required for endothelial cell proliferation during vasculogenesis, but play critical roles in vascular maturation, maintenance of integrity and remodeling. Also reported was that an activating mutation in TEK caused congenital venous malformations in two families with the implication that the TEK signaling pathway plays a pivotal role in endothelial cell-smooth muscle cell interaction in venous morphogenesis (19) . It is now considered that TEK controls the capability of endothelial cells to recruit peri-endothelial support cells to stabilize the structure of blood vessels and modulate their function (18, 20, 21) .
Recently, a ligand for the TEK receptor, termed Angiopoietin-1, was cloned by secretion-trap expression cloning (22) . The nucleotide sequence of Angiopoietin-1 cDNA contains an open reading frame encoding 498 amino acids including a coiled-coil domain and a fibrinogen-like domain. Although Angiopoietin-1 does not affect endothelial cell growth in culture, mice lacking Angiopoietin-1 display angiogenic deficits similar to but slightly less severe than those of mice lacking TEK, and this finding supports the putative roles for TEK and Angiopoietin-1 in angiogenesis (22, 23) . A relative of Angiopoietin-1, termed Angiopoietin-2, has also been reported to act as a natural antagonist for Angiopoietin-1 and TEK in angiogenesis (24) . This means that the signals mediated by TEK are precisely regulated by both positive and negative regulators in vivo.
Endothelial and hematopoietic lineages are closely linked, and several molecules are expressed on both lineage cells, including Flk-1, Flt-1 and CD34. Therefore, investigating the expression spectrum and functions of these molecules may provide information about the development of the endothelialhematopoietic system. TEK and TIE are two of the molecules thought to be involved in hematopoiesis during the ontogeny and differentiation of HSC as well as in angiogenesis. We previously cloned the genes encoding TEK and TIE from highly enriched murine HSC (Lin -c-KIT ϩ Sca-1 ϩ cells) and confirmed their expression in murine HSC using mAb (15, 25) . We also reported that human TIE is predominantly expressed in HSC and B lymphocytes (26) . These findings indicate that TEK and TIE have some significant functions in HSC as well. In this study, we established mAb against the extracellular domain of human TEK and demonstrated its specific expression in hematopoietic progenitor cells. We further characterized the biological effects of Angiopoietin-1 and -2, and propounded that these two ligands probably modulate the direct connection between hematopoietic progenitor cells and their microenvironment.
Methods

Establishment of TEK-overexpressing transformants
Full-length cDNA of human TEK was isolated from a human placenta cDNA library by plaque hybridization method. In short, a total of 1ϫ10 6 clones were screened using as a probe the 215 bp KpnI-BamHI segment in human TEK cDNA including the translation starting codon. One positive clone was subcloned into pBluescript (Stratagene, La Jolla, CA) and subjected to DNA sequencing, which revealed that this clone contains the whole coding region of human TEK cDNA.
The full-length TEK cDNA was re-subcloned into an expression vector with the chicken β-actin promoter and introduced into IL-3-dependent Ba/F3 cells by electroporation. Among G418-resistant clones, the one with the highest level of receptor expression (BaF/TEK) was used in this study as well as the previously established human TIE-overexpressing Ba/ F3 cells (BaF/TIE) (26) . Ba/F3 cells transfected with vector alone (BaF/vector) were used as negative controls.
Generation of monoclonal and polyclonal antibodies against TEK BALB/c mice purchased from SLC (Hamamatsu, Japan) were immunized i.p. with purified human TEK extracellular domain tagged with human Fc or mouse Fc (TEK-Fc). Mouse myeloma cells (P3-X63-Ag8-U1; P3U1) were fused with the spleen cells from the immunized mice. Positive hybridoma clones were screened with a FACS using BaF/TEK cells as indicators. Two clones that produced anti-human TEK mAb were obtained and designated C9C3 and A1F9. Secreted mAb were purified using a Protein A-Sepharose column (BioRad, Hercules, CA) and biotinylated. The IgG fraction of the antiserum obtained from the immunized mice was purified and used as mouse anti-human TEK polyclonal antibody.
Immunoprecipitation and Western blotting.
Cells were solubilized with lysis buffer (1% Triton-X100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF, 50 mg/ml aprotinin). The lysates were incubated with anti-TEK mAb for 6 h at 4°C. Immunocomplexes were collected on Protein G-Sepharose (Pharmacia, Uppsala, Sweden), washed 3 times with lysis buffer and boiled for 3 min in SDS-PAGE sample buffer with 5% 2-mercaptoethanol (2-ME). After electrophoresis, proteins were transferred to PVDF membranes (Nihon Millipore, Yonezawa, Japan) and then probed with the polyclonal antibody against TEK C-terminal synthetic peptide (Santa Cruz Biotechnology, Santa Cruz, CA). The specific binding was detected using the ECL system (Amersham, Amersham, UK).
To confirm the specificity of anti-TEK mAb, the following blocking experiments were performed in Western blotting and FACS. Specific binding of anti-TEK mAb or polyclonal antibody to TEK protein was blocked by preincubating the antibody with TEK C-terminal synthetic peptide or a 100-fold molar excess of TEK-Fc for 1 h at room temperature before staining.
Binding of Angiopoietin-1 and -2 to TEK Before biological assays, the binding affinities of Angiopoietin-1 and -2 were analyzed using a BIAcore biosensor (Pharmacia). Purified human recombinant Angiopoietin-1 (185 µg/ml) and -2 (87 µg/ml) were used in this study. Recombinant angiopoietin-1 is a genetically engineered variant of Angiopoietin-1 (24) . TEK-Fc protein at a concentration of 25 µg/ml was coupled to BIAcore sensor chips (Pharmacia) and the binding affinity (resonance units) was measured and analyzed according to the manufacturer's instructions.
In vivo tyrosine phosphorylation assay.
BaF/TEK cells incubated for 12 h under IL-3-free conditions were used for the phosphorylation assay. The cells were first incubated with 20 µg/ml preimmune IgG or 5 µg/ml anti-TEK polyclonal antibody at 37°C for 10 min. In another experiment, the cells were incubated with 2 µg/ml Angiopoietin-1, 2 µg/ml Angiopoietin-2, 2 µg/ml Angiopoietin-1 with a 10-fold molar excess of Angiopoietin-2 and 2 µg/ml Angiopoietin-1 preincubated with a 50-fold molar excess of TEK-Fc. Phosphorylation-inducing activity of Angiopoietin-2 was examined at a concentration of 0.2-20 µg/ml.
After the stimulation, the cells were solubilized with lysis buffer (1% Triton X-100, 50 mM HEPES, pH 7.4, 10% glycerol, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 4 mM EDTA, 2 mM sodium orthovanadate, 50 mg/ml aprotinin, 1 mM PMSF, 100 mM leupeptin and 25 mM pepstatin A). TEK proteins were immunoprecipitated from the cell lysates and autophosphorylation of tyrosine residues was evaluated with anti-phosphotyrosine mAb, 4G10 (Upstate Biotechnology, Lake Placid, NY), by Western blotting.
Preparation of human bone marrow cells, cord blood cells and peripheral blood cells.
Bone marrow cells were harvested from normal healthy volunteers with prior approval. Cells diluted with PBS were centrifuged over Ficoll-Metrizoate (Ficoll-Paque; Pharmacia) for 30 min at 400 g. Mononuclear cells recovered from the interface were then overlaid on PBS containing 10% BSA (Sigma, St Louis, MO) and centrifuged for 10 min at 100 g to remove platelets. Cell pellets were suspended in PBS containing 5% FCS and 0.01% sodium azide. Cord blood and peripheral mononuclear cells were also prepared in a similar way.
FACS analysis and cell sorting.
Bone marrow mononuclear cells (BMMNC), cord blood mononuclear cells and peripheral blood mononuclear cells separated as described above were used for preparing lineage marker-negative cells so that we could focus on early hematopoietic progenitor cells. In short, the cells were incubated with a cocktail of mouse anti-human lineage (Lin) marker antibodies comprising CD3, CD4, CD8, CD13, CD14, CD19 (PharMingen, San Diego, CA) and glycophorin A (Immunotech, Marseilles, France) for 30 min on ice. After being washed twice with PBS, the cells were mixed with Dynabeads M-450 sheep anti-mouse IgG (Dynal, Great Neck, NY) at a 1:40 cell:bead ratio and incubated for 40 min on ice. Then the bead-free cells were separated from bead-bound cells and free beads in a magnetic field, and used as lineage marker-negative (Lin -) cells.
After Fc receptor blocking with CD 32/16 mAb (PharMingen), the cells were stained with the biotinylated anti-TEK mAb, followed by allophycocyanin-conjugated streptavidin (Caltag, San Francisco, CA) in conjunction with the following mAb; FITC-conjugated CD34 mAb (NU-4A1; Nichirei, Tokyo, Japan), phycoerythrin (PE)-conjugated anti-c-KIT mAb (NUc-KIT; Nichirei), PE-conjugated CD38 mAb (Leu-17; Becton Dickinson Immunocytometry System, San Jose, CA), PEconjugated CD33 mAb (WM53; PharMingen), PE-conjugated CD13 mAb (WM15; PharMingen), PE-conjugated CD14 mAb (TÜ K4; Dako, Glostrup, Denmark), PE-conjugated CD3 mAb (NU-T3; Nichirei), FITC-conjugated CD19 mAb (HD37; Dako) and FITC-conjugated anti-glycophorin A mAb (D2.10; Immunotech). FACS analysis and cell sorting were performed on a FACS vantage (Becton Dickinson) equipped with 488 argon and 632 He/Ne lasers. Data from Ͼ10,000 mononuclear cells was collected and analyzed on Lysys II software (Becton Dickinson). The fluorescence intensity of individual cells was measured as relative fluorescence units. Residual erythrocytes and dead cells were gated out using forward/side scatter channels at the time of data analysis and sorting.
Human umbilical cord vein endothelial cells (HUVEC; Kurabo, Osaka, Japan) were also stained with biotinylated anti-TEK mAb followed by FITC-conjugated streptavidin (Gibco, Grand Island, NY) to confirm the expression of TEK protein on them by FACS analysis.
Colony assay in methylcellulose culture
Sorted cells were embedded in 1 ml of 1.3% methylcellulose (1500 cp; Aldrich, Milwaukee, WI), 30% FCS, 1% deionized BSA, 5ϫ10 -5 M 2-ME (Sigma), 100 ng/ml SCF, 2 U/ml recombinant human erythropoietin (Epo) and 20 ng/ml IL-3, with or without 2 µg/ml Angiopoietin-1 in IMDM. The culture dishes were incubated in a humidified atmosphere at 37°C and 5% CO 2 .
To examine the effect of the TEK ligand on cell proliferation, BaF/TEK cells were cultured in 1.3% methylcellulose containing various concentrations of IL-3 with or without 2 µg/ml Angiopoietin-1 and the number of formed colonies was counted on day 7. We also cultured BaF/TEK cells without IL-3 and investigated whether addition of Angiopoietin-1 could rescue BaF/TEK cells from apoptotic death.
Detection of Angiopoietin mRNAs by RT-PCR
BMMNC were cultured in IMDM containing 12.5% FCS, 12.5% horse serum (Summit Biotechnology, Greeley, CO), 50 µM 2-ME and 1 µM hydrocortisone (Japan Upjohn, Tokyo, Japan). The supernatant was discarded after 3 days and remaining cells were cultured in fresh medium for another 3-4 days until adherent cells appeared in clusters. These adherent cells were replated and cultured Ͼ3 weeks before used as bone marrow stromal cells.
Total RNAs were extracted from 1ϫ10 6 BMMNC and bone marrow stromal cells using the acid guanidinium thiocyanatephenol-chloroform method. The first-strand cDNAs were synthesized from 1 µg of the total RNAs using Superscript II reverse transcriptase and random hexamer oligonucleotides (Life Technologies, Grand Island, NY). Ten percent of the cDNAs was applied to amplification as templates. The cycling parameters were 1 min at 94°C, 2 min at 60°C and 3 min at 72°C for 40 cycles. The primer sequences were as follows: Angiopoietin-1 sense, 5Ј-TTCCTCGCTGCCATTCTGACT-3Ј; Angiopoietin-1 antisense, 5Ј-CTCCGACTTGATGTTTTCCAC-3Ј; Angiopoietin-2 sense, 5Ј-CTGAGCTGTGATCTTGTCTTG-3Ј; Angiopoietin-2 antisense, 5Ј-GTTCTGTACTGCATTCTGC-TG-3Ј; human β-actin (reference gene) sense, 5Ј-CTGGACTT-CGAGCAAGAGAT-3Ј; human β-actin antisense, 5Ј-TCGTCATACTCCTGCTTGCT-3Ј. The expected length of the PCR products was 308 bp for Angiopoietin-1, 332 bp for Angiopoietin-2 and 400 bp for β-actin. Ten percent of these reaction mixtures was electrophoresed on 2% agarose gel and stained with ethidium bromide.
Effect of Angiopoietins on adhesion of TEK-transfected hematopoietic cells
To investigate whether the signaling via TEK receptor is involved in cell adhesion, BaF/TEK cells were cultured on collagen type I-coated 24-well plates (Iwaki Glass, Chiba, Japan) with or without various concentrations of Angiopoietins (0.1, 0.3, 0.5 and 1 µg/ml). One hour later, the non-adherent and the adherent cells were separately harvested by gentle pipetting or tripsinization respectively, and the percentage of the adherent cells was calculated as the number of the adherent cells divided by that of the total cells. Angiopoietins preincubated with a 100-fold molar excess of TEK-Fc were also used for blocking experiments.
Similarly, BaF/TEK cells were co-cultured with the semiconfluent bone marrow stromal cells prepared in the method described above with or without 50 µg/ml TEK-Fc and the percentage of the BaF/TEK cells adhering to a layer of stromal cells was estimated 1 h later.
Results
Characterization of anti-TEK mAb
We established two mAb against the extracellular domain of human TEK protein, designated C9C3 and A1F9. Since both were IgG1 and showed a similar staining pattern on BaF/TEK cells and bone marrow cells, C9C3 was used in the following study. FACS analysis showed that this biotinylated mAb reacted with BaF/TEK cells and HUVEC, but not with BaF/ vector cells (Fig. 1A, B and C) . A 100-fold molar excess of TEK-Fc completely blocked the binding of the mAb to BaF/ TEK cells and HUVEC, which demonstrated the specificity of the mAb for human TEK protein ( Fig. 1A and B) . The mAb did not cross-react with BaF/TIE cells in spite of high homology of human TEK protein with human TIE protein (Fig. 1D) .
C9C3 mAb immunoprecipitated two proteins of different mol. wt, which were detected by rabbit anti-TEK polyclonal antibody, from each lysate of BaF/TEK cells and HUVEC but no proteins from that of BaF/vector cells ( Fig. 2A, lanes 1, 2  and 4) . The molecular masses of these two proteins were 145 and 136 kDa respectively, and the 145 kDa protein surpassed the 136 kDa protein in quantity. A 100-fold molar excess of the TEK C-terminal synthetic peptide abolished specific binding of rabbit anti-TEK polyclonal antibody in Western blotting, which indicated that both of these forms were TEK proteins ( Fig. 2A, lanes 3 and 5) .
Binding of Angiopoietin-1 and -2 to TEK Angiopoietin-1 and -2 are two distinct molecules of TEK ligands that were recently cloned. BIAcore biosensor analysis revealed that both Angiopoietin-1 and -2 bind to immobilized TEK-Fc with almost equivalent affinity (Fig. 3A) . The affinity of Angiopoietin-1 completely vanished when it was preincubated with a 50-fold molar excess of TEK-Fc (Fig. 3A) . This indicates that the binding of Angiopoietin-1 is receptor specific. A mixture of 2 µg/ml Angiopoietin-1 and 20 µg/ml Angiopoietin-2 showed the highest affinity; 5-6 times that of each molecule alone (Fig. 3A) . In vivo phosphorylation of TEK protein.
Since it is well known that certain antibodies against receptor proteins are agonistic, we analyzed whether the polyclonal antibody against the extracellular domain of TEK has such an activity. The polyclonal antibody induced tyrosine phosphorylation of 145 kDa TEK on BaF/TEK cells but not 136 kDa TEK (Fig. 2B ). This result indicated that 145 kDa TEK is a functional molecule and that 136 kDa TEK is an immature cytoplasmic protein as is the case with murine TEK 32 .
Angiopoietin-1 and -2 were then applied to in vivo phosphorylation assay. Angiopoietin-1 at a concentration of 2 µg/ml plainly induced phosphorylation of 145 kDa TEK on BaF/TEK cells and this phosphorylation was completely blocked when Angiopoietin-1 was preincubated with an excessive amount of TEK-Fc (Fig. 3B, lanes 1, 2 and 5 ). Angiopoietin-2 at a concentration of 2 µg/ml also caused 145 kDa TEK phosphorylation but the effect was not so apparent as that of Angiopoietin-1 (Fig. 3B, lane 3) . The phosphorylation-inducing activity of Angiopoietin-2 was consistently weaker than that of 2 µg/ ml Angiopoietin-1 regardless of the concentration (0.2-20 µg/ ml) (data not shown). In addition, an abundant amount of Angiopoietin-2 weakened the phosphorylation-inducing activity of Angiopoietin-1 (Fig. 3B, lane 4) . These results indicated that Angiopoietin-1 is the primary agonist of TEK and Angiopoietin-2 is the vice-activator. Immunoprecipitates were Western blotted with anti-phosphotyrosine antibody (upper panels) and reprobed with polyclonal antibody against the C-terminus of TEK (lower panels).
Expression of TEK protein on human bone marrow hematopoietic cells
Bone marrow cells harvested from healthy volunteers were evaluated as to expression of TEK protein by FACS. In conjunction with C9C3 anti-TEK mAb, mAb against CD34 and c-KIT were used as hematopoietic stem cell markers, and mAb against CD33, CD13, CD14, CD3, CD19 and glycophorin A were used as differentiated hematopoietic cell markers.
In hematopoietic stem cells, TEK was expressed in 27% of CD34 ϩ cells and 20% of c-KIT ϩ cells as well as in 3% of CD34 -or c-KIT -cells ( Fig. 4A and B) . When we focused on CD38 -cells, TEK was expressed in 26% of CD34 ϩ CD38 -cells, the supposedly most primitive HSC (Fig. 4A) . Expression of TEK was also detected in 20% of CD19 ϩ B cells, but barely detectable in CD3 ϩ T cells (Fig. 4C) . Neither granulocyte macrophage cells (CD33 ϩ , CD13 ϩ or CD14 ϩ ) nor erythroid cells (glycophorin A ϩ ) expressed TEK protein (data not shown). These expression patterns were shared by cord blood cells and peripheral blood cells (data not shown). These findings confirmed that TEK is expressed in a subset of HSC and B lymphocytes.
In vitro colony assay and effects of Angiopoietin-1 Bone marrow CD34 ϩ cells fractionated and sorted according to TEK expression were cultured in methylcellulose medium containing SCF, IL-3 and Epo. After 14 days, CD34 ϩ TEKcells formed more erythroid and mixed colonies than CD34 ϩ TEK ϩ cells (Fig. 5, stippled bars) . There was no significant difference in granulocyte macrophage colony formation between the two fractions (Fig. 5, open bars) .
We investigated whether a TEK ligand, Angiopoietin-1, has any influence on the growth of TEK ϩ cells. According to the result of colony assay, Angiopoietin-1 did not affect colony formation from bone marrow CD34 ϩ TEK ϩ cells nor proliferation of BaF/TEK cells regardless of IL-3 concentration (Figs 5 and 6A). These findings suggested that Angiopoietin-1 has no effect on proliferation of hematopoietic cells and the difference in colony-forming activity between CD34 ϩ TEK ϩ cells and CD34 ϩ TEK -cells is attributable to unknown factors. Angiopoietin-1 could not inhibit the apoptosis of BaF/TEK cells in the absence of IL-3 ( Fig. 6B ) and did not cause any morphological changes in BaF/TEK cells (data not shown). Similarly, Angiopoietin-2 did not promote BaF/TEK cell proliferation nor inhibit its apoptosis (data not shown).
Detection of Angiopoietin mRNA by RT-PCR
To clarify the origins of TEK ligands in the bone marrow, we analyzed the expression of Angiopoietin mRNAs by RT-PCR. As shown in Fig. 7 , both mRNAs of Angiopoietin-1 and -2 were detected in bone marrow stromal cells, though mRNA of Angiopoietin-2 was not so obvious as that of Angiopoietin-1. Neither mRNA was detected in BMMNC.
Effects of Angiopoietins on adhesion of TEK-transfected hematopoietic cells.
BaF/TEK cells were cultured on collagen type I-coated plates and the percentage of the adherent cells was estimated after 1 h. Angiopoietin-1 and, to a lesser degree, Angiopoietin-2 dose-dependently promoted the adhesion of BaF/TEK cells to the bottom of the plates (Fig. 8A ) and this effect was completely purged by a 100-fold molar excess of TEK-Fc (data not shown). BaF/vector cells did not show the significant increase of adhesion by the addition of Angiopoietins.
Because our results of RT-PCR showed endogenous Angiopoietins were secreted by bone marrow stromal cells, we examined whether an excessive amount of soluble TEK-Fc could interrupt BaF/TEK cell adhesion to a layer of bone marrow stromal cells. A great majority (76.1%) of BaF/TEK cells co-cultured with stromal cells adhered to a layer of stromal cells within 1 h, but the percentage of the adherent cells decreased to 51.6% when 50 µg/ml TEK-Fc was added in the culture medium (Fig. 8B) . The effect of TEK-Fc is statistically significant (P Ͻ 0.01).
Discussion
We previously cloned two related RTK genes, TIE and TEK, from highly enriched murine HSC (Lin -c-KIT ϩ Sca-1 ϩ cells), and confirmed their specific expression in murine HSC and some undifferentiated hematopoietic cell lines (15, 25) . In the present study, we showed that human TEK is expressed in hematopoietic progenitor cells and B lymphocytes. This expression profile is the same as human TIE (26) .
We first established mAb against the extracellular domain of TEK protein. One of the mAb, designated C9C3, was used throughout this study. In FACS analysis (Fig. 1) , C9C3 mAb showed specific reactivity to TEK expressed in BaF/TEK cells and HUVEC, but did not cross-react with TIE (Fig. 1) . Two forms of TEK protein, 145 and 136 kDa, were detected in the lysates of BaF/TEK and HUVEC in Western blotting (Fig. 2) . Our previous results showed that there are two forms of murine TEK or human TIE with different mol. wt and those of larger mol. wt are the mature cell-surface proteins according to phosphorylation and cell-surface labeling experiments (25, 26) . As shown in Fig. 2(B) , the anti-TEK polyclonal antibody, purified from the immunized mouse sera, induced the phosphorylation of only 145 kDa TEK. This auto-phosphorylating signal is probably transduced by cell-surface TEK whose extracellular domains are cross-linked by the anti-TEK polyclonal antibodies. These results of Western blotting and phosphorylation assay are absolutely compatible with our previous findings, so human 145 kDa TEK is supposedly a mature functional form.
FACS analysis of bone marrow cells revealed the expression of TEK in CD34 ϩ cells, c-KIT ϩ cells and CD19 ϩ cells (Fig. 4) . The percentage of TEK ϩ cells in these fractions was 27, 20 and 20% respectively. This expression pattern resembles that of human TIE (26) . Human TIE was expressed in 42% of CD34 ϩ cells, 17% of c-KIT ϩ cells and 8% of CD19 ϩ cells. When we focused on the CD34 ϩ CD38 -fraction, which is regarded as the most primitive stem cell fraction found to date (27), we found TEK ϩ cells (26%) to be much fewer than TIE ϩ cells (81%). Moreover, although TIE ϩ cells existed preferentially in CD34 ϩ or c-KIT ϩ fractions, TEK ϩ cells existed both in CD34 ϩ and CD34 -or c-KIT ϩ and c-KIT -fractions in a similar proportion. TEK was also expressed in the CD33 -/low fraction (data not shown). These findings indicate that TEK as well as TIE segregates specific subpopulation in HSC but the spectrum of TEK expression is shifted to a little more differentiated stage of HSC compared with that of TIE expression.
According to the colony assay of sorted bone marrow cells, CD34 ϩ TEK ϩ cells contained significantly smaller number of BFU-E and CFU-Mix than CD34 ϩ TEK -cells (Fig. 5) . Since the number of CFU-GM was almost the same between these two fractions, it was concluded that CD34 ϩ TEK ϩ cells have less colony-forming ability than CD34 ϩ TEK -cells. We previously reported that CD34 ϩ TIE ϩ and CD34 ϩ TIE -cells show almost equal colony-forming abilities, whereas KIT ϩ TIE ϩ cells contained more CFU-GM than KIT ϩ TIE -cells (26) . These data might well represent the distinct expression between TEK and TIE in HSC. To further investigate the distributional and functional difference between TEK and TIE, we are now committed to the analysis of the bone marrow cells stained with anti-TEK and anti-TIE mAb simultaneously. Although the direct labeling of TEK and TIE was not as clear as the biotinavidin system, preliminary experiments show the existence of TEK and TIE double-positive cells.
Angiopoietin-1 is a biological ligand for TEK recently identified from a human neuroepithelioma cell line, SHEP1-1 and a mouse myoblast cell line, C2C12ras (22) . Angiopoietin-1 induced phosphorylation of TEK in primary endothelial cells but did not directly promote their growth. The mice lacking Angiopoietin-1 displayed angiogenic deficits similar to but slightly less severe than those of mice lacking TEK (23) . Angiopoietin-2 is another ligand for TEK isolated as a relative of Angiopoietin-1 (24). Angiopoietin-2 exhibited similar binding affinity for TEK as Angiopoietin-1 but had no phosphorylation-inducing activity in endothelial cells. That Angiopoietin-2 overexpressing transgenic mice basically recapitulated the vascular defects in Angiopoietin-1 or TEK-lacking mice supported the hypothesis that Angiopoietin-2 is a naturally occurring antagonist of Angiopoietin-1 and TEK. It should be noted here that Angiopoietin-2 induced phosphorylation of TEK We approached the functional analysis of the TEK-TEK ligand signaling pathway in hematopoietic cells using Angiopoietin-1 and -2. Angiopoietin-1 and -2 showed similar binding affinity for TEK by BIAcore biosensor analysis (Fig. 3A) . Maisonpierre et al. showed the similar data using a binding assay to nitrocellulose-immobilized ligands (K d 3 nM, by Scatchard analysis) (24) . In phosphorylation assay, both Angiopoietin-1 and -2 induced TEK phosphorylation in BaF/TEK cells but the activity of Angiopoietin-2 was much weaker, supported by the result that a 10-fold molar excess of Angiopoietin-2 weakened the phosphorylationinducing activity of Angiopoietin-1 (Fig. 3B) . Similarly, TEK was phosphorylated by addition of Angiopoietin-1 or -2 in BaF cells transfected with murine TEK (data not shown). These findings contrast with the fact that Angiopoietin-2 showed no phosphorylation-inducing activity and was considered to be a natural antagonist for TEK in vascular endothelial cells (24) , and suggest a possibility that in hematopoietic cells Angiopoietin-2 acts either as the viceactivator by itself or as a suppressor of the effect of coexisting Angiopoietin-1.
As shown in Fig. 6(A) , Angiopoietin-1 did not promote the growth of BaF/TEK cells and this was confirmed by thymidine incorporation analysis (data not shown). Because of a possibility that Ba/F3 cells are lacking in the molecules essential for the TEK-mediated signal transduction, the effect of Angiopoietin-1 was then assessed on bone marrow hematopoietic cells which endogenously express TEK. Angiopoietin-1 had no effect on colony formation by CD34 ϩ TEK ϩ cells (Fig. 5) . These results agree with those of a preceding report on vascular endothelial cells (22) and support that the TEK-TEK ligand signaling pathway is not involved in cell proliferation. Moreover, Angiopoietin-1 alone could not support the prolif- Fig. 7 . RT-PCR analysis of TEK ligand mRNAs expression in bone marrow components. The first-strand cDNAs synthesized from total RNAs of BMMNC and stromal cells were analyzed for the presence of specific sequences for Angiopoietin-1 and -2. Human β-actin was used as a reference gene for semiquantitative analysis. Total RNAs processed without reverse transcriptase were applied to PCR amplification using β-actin primers (RT-).
eration of BaF/TEK cells unlike the effect of MSP on BaF/STK cells in our previous work (28) (Fig. 6B) . Also, Angiopoietin-2 had no effect on the proliferation or the apoptosis of BaF/ TEK cells (data not shown).
On the basis that Angiopoietin-1 was cloned from mesenchymal cell lines (22) and overexpression of TEK in vascular endothelial cells results in decreased smooth muscle cell recruitment (19) , a hypothesis has been proposed that expression of Angiopoietins by mesenchymal cells is controlled by negative feedback from endothelial cells and the TEK ligand loop is coupled to platelet-derived growth factor/transforming growth factor β-mediated chemotaxis, proliferation and differentiation of smooth muscle cells (19) . When it comes to hematopoiesis, hematopoietic cells require direct connection with their microenvironment, consisting of stromal cells and extracellular matrixes, for proliferation, differentiation and migration as well as homing in the bone marrow (29) (30) (31) (32) (33) (34) (35) . That Angiopoietins are detected in bone marrow stromal cells (Fig. 7) indicates possible hematopoietic cell-stromal cell interaction via TEK receptor. As shown in Fig. 8(A) , Angiopoietin-1 or -2 promoted BaF/TEK cell adhesion to a collagen type I matrix. The effect of Angiopoietin-1 is more prominent than that of Angiopoietin-2, according to their phosphorylationinducing activity of TEK receptor. Moreover, when BaF/TEK cells were cultured on a layer of bone marrow stromal cells, addition of 50 µg/ml TEK-Fc in this co-culture system decreased the proportion of the BaF/TEK cells adhering to the stromal cell layer, probably by blocking endogenous Angiopoietins secreted by stromal cells (Fig. 8B) . These findings supported a putative role of the TEK-TEK ligand signaling pathway in the direct interaction between hematopoietic cells and their microenvironment. Some cytokines including SCF, IL-3 and thrombopoietin have been shown to activate β 1 integrins expressed on hematopoietic progenitor cells and enhance their adhesiveness to extracellular matrix proteins (36) (37) (38) (39) (40) . β 1 integrins are involved in the attachment of TEK ϩ cells to fibronectin (manuscript in preparation). In BaF/TEK cells, stimulation of TEK receptor might lead to activation of integrin families, thereby prompting the adhesion of BaF/TEK cells to a collagen matrix or a layer of stromal cells. The structural feature of the extracellular domain of TEK, containing EGF-like domains and fibronectin type III repeats, also implies its involvement in cell adhesion.
We have established mAb against human TEK protein, the first reported anti-human TEK mAb to our knowledge. We then confirmed using this mAb that human TEK is expressed in HSC and B lymphocytes as well as in vascular endothelial cells. Among newly cloned TEK ligands, Angiopoietin-1 was considered to be the primary activator, and Angiopoietin-2 seemed to serve as an exquisite and flexible regulator of the TEK-TEK ligand signaling pathway. TEK phosphorylation induced by Angiopoietins promoted the adhesion of TEKtransfected hematopoietic cells to a collagen matrix or a layer of stromal cells, suggesting the involvement of TEK in hematopoietic cell-microenvironment interaction. Identification of precise roles of the TEK-TEK ligand signaling pathway in hematopoiesis may give us a new insight into the biology of HSC.
